Research programme: EphB4 receptor/ligand modulators - VasGene

Drug Profile

Research programme: EphB4 receptor/ligand modulators - VasGene

Alternative Names: anti-EphB4 monoclonal antibody - VasGene; EphB4 neutralising Ab - VasGene; EphB4 neutralising antibody - VasGene; EphB4 neutralizing Ab - VasGene; EphB4 receptor tyrosine kinase inhibitor - VasGene; EphB4 RTK inhibitor - VasGene; EphB4 soluble receptor - VasGene; EphB4-131; Ephrin B2 agonist - VasGene; Vas 02; Vas 101; Vas 102; Vas 103; Vas 104; Vas 105; VasG3 MAb; VasG4 MAb; VasG5 MAb

Latest Information Update: 22 Jan 2016

Price : $50

At a glance

  • Originator VasGene Therapeutics
  • Class Antisense oligonucleotides; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action EphB4 inhibitors; Ephrin-B2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration; Cancer; Eye disorders
  • Discontinued Vascular disorders

Most Recent Events

  • 22 Jan 2016 Discontinued - Preclinical for Vascular disorders in USA (Parenteral)
  • 22 Jan 2016 Research programme is still in preclinical trials for cancer, age-related macular degeneration and diabetic eye disorders in the US (VasGene Therapeutics pipeline, January 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top